PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nature. Author manuscript; available in PMC 2010 November 24.
Published in final edited form as:
PMCID: PMC2990914
NIHMSID: NIHMS250218

Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands

Abstract

Reciprocity of inflammation, oxidative stress and neovascularization is emerging as an important mechanism underlying numerous processes from tissue healing/remodeling to cancer progression1,2. Whereas the mechanism of hypoxia-driven angiogenesis is well understood3,4, the link between inflammation-induced oxidation and de novo blood vessel growth remains obscure. Here we show that the end products of lipid oxidation, ω-(2-carboxyethyl)pyrrole (CEP) and other related pyrroles5, are generated during inflammation and wound healing and accumulate at high levels in aging tissues and in highly vascularized tumors. The molecular patterns of carboxyalkylpyrroles are recognized by Toll-like receptor 2 (TLR2), but not TLR4 nor scavenger receptors on endothelial cells (ECs), leading to a VEGF-independent angiogenic response. CEP promoted angiogenesis in hind limb ischemia and wound healing models through TLR2 signaling in a MyD88-dependent manner. Neutralization of endogenous carboxyalkylpyrroles impaired wound healing and tissue re-vascularization and diminished tumor angiogenesis. Both TLR2 and MyD88 are required for CEP-induced stimulation of Rac1 and endothelial migration. Together, these findings establish a new function of TLR2 as a sensor of oxidation-associated molecular patterns, providing a key link connecting inflammation, oxidative stress, innate immunity and angiogenesis.

Angiogenesis can either promote host defense and tissue repair or exacerbate organ dysfunction resulting in disease. In many pathologies, angiogenesis and inflammation6 are intimately related. Inflammatory cells release proangiogenic growth factors, including VEGF7, which facilitate neovascularization. Newly-formed blood vessels enhance inflammatory cell recruitment, thereby promoting chronic inflammation. Leukocytes, in particular myeloid cells, are guided by8 and contribute to9 oxidative stress and the generation of oxidative products, including hydroxy-ω-oxoalkenoic acids and their esters (Supplementary Fig. 1). When present in oxidized phospholipids, these molecules are recognized by the scavenger receptor CD36 and contribute to atherosclerotic progression and platelet hyper-reactivity10,11. Hydrolysis followed by reaction of the resulting unesterified hydroxy-ω-oxoalkenoic acids with proteins, or reaction of the esterified hydroxy-ω-oxoalkenoic acids with proteins followed by hydrolysis, gives rise to a family of carboxyalkylpyrrole protein adducts (CAP), among them CEP and similarly-modified compounds (Supplementary Fig. 1). These adducts, present in oxidized LDL, accumulate in atherosclerotic plaques and are found in the retina12, where they promote choroidal neovascularization and age-related macular degeneration5,13.

These adducts, CEP in particular, are transiently present during wound healing, reaching a maximum 3d after injury before returning to original levels when the wound is healed (Fig. 1a,b and Supplementary Fig. 2a–c). This increase coincides with the recruitment of bone marrow-derived cells (Supplementary Fig. 2b), which generate additional oxidants9. A substantial proportion of CEP (~60% at 3d, ~50% at 7d) is present in F4/80+ macrophages (Fig. 1c) but not in Gr-1+ neutrophils (Supplementary Fig. 2c). High levels of CEP coincide with intense wound vascularization, suggesting a role for CEP in wound angiogenesis (Fig. 1a,b). In contrast to wounds, CEP levels were continuously elevated in pathological states. In melanoma, exhibiting excessive vascularization and inflammation (assessed by CD31 and CD68 staining, respectively), CEP levels were elevated 6-fold (Fig. 1d). Likewise, in murine melanoma, CEP levels were elevated 9-fold (Supplementary Fig. 3). In contrast to wound and tumor tissues, CEP in uninjured muscle was confined to arteriolar smooth muscle cells (Fig. 1e). Notably, CEP accumulation increased in aging tissues (Fig. 1f). These data suggest a role of CEP in inflammation-associated vascularization.

Fig. 1Fig. 1
CEP, an end product of lipid oxidation, is present in wounds, elevated in melanoma and accumulated in aging tissues

When tested on ECs from human umbilical vein, mouse lung or aorta, CEP had proangiogenic effect comparable to VEGF, as evaluated in various assays (Fig. 2, Supplementary Fig. 4 and S5). Similar to VEGF, the effect of CEP was integrin-mediated (Supplementary Fig. 5b). The proangiogenic effect was dependent on the presence of pyrrole adducts, and the protein moiety did not influence CEP’s effect, as adducts coupled to MSA, HSA or a dipeptide were equally effective (Fig. 2a and Supplementary Fig. 4).

Fig. 2Fig. 2Fig. 2
Proangiogenic effects of oxidized adducts are dependent on pyrrole moiety and are mediated by TLR2 but not VEGFR signaling

However, in contrast to VEGF, stimulation of ECs with CEP did not result in VEGFR2 phosphorylation (Supplementary Fig. 6). Moreover, CEP-induced effects both in vitro and in vivo were not reduced by the VEGFR kinase inhibitor AAL-99314 at the concentration sufficient to block VEGF-A effects (Fig. 2b,c), vehicle alone having no effect (data not shown). In a wound healing assay, CEP accelerated vascularization and wound closure; this effect was unimpeded by AAL-993 which delayed wound closure in control animals (Fig. 2d). Thus, CEP activates the proangiogenic responses independently of VEGF/VEGFR2 signaling. Adducts from the same family of CAPs (Supplementary Fig. 1), represented by CPP (carboxypropylpyrrole), were also proangiogenic (Fig. 2a, Supplementary Fig. 4a,b, and 5a), indicating that the ECs respond to the molecular pattern rather than to a particular chemical moiety.

To identify receptors mediating CEP-induced angiogenesis, we tested the role of CD36 and SR-BI scavenger receptors, as CD36 recognizes precursors of CAPs11. Both CEP and CPP adducts were as effective on CD36−/− and SR-BI−/− ECs as on wild type cells (Supplementary Fig. 7a–d), indicating that scavenger receptors are not involved in recognition of these adducts.

Since ECs respond to CAP’s molecular pattern, which is a characteristic feature of oxidative stress, we hypothesized the involvement of Toll-like family receptors (TLRs) in CEP-induced angiogenesis. TLRs recognize a number of damage associated molecular patterns including pathogen-associated molecular patterns (reviewed in15,16) and ligands of host origin1722, contributing to immune defense and to sterile inflammation, respectively. We focused on TLR2 and TLR4 since they are expressed on the endothelium, are implicated in angiogenesis23 and are known to recognize a broad range of protein and lipid ligands24. Anti-TLR2, but not TLR4 antibodies, inhibited CEP-, but not VEGF-induced, tube formation (Fig. 2e) and EC migration (Supplementary Fig. 8a). To further address the role of TLR2 in CEP-driven angiogenesis, ECs from TLR2−/− mice were compared to TLR2+/+ controls. TLR2−/− ECs did not respond to CEP or CPP treatment in a number of in vitro assays; in contrast, VEGF-triggered responses were not affected by the lack of TLR2 (Fig. 2f, Supplementary Fig. 8b and 9a). To confirm the role of TLR2 in EC proangiogenic responses, we tested the TLR2 synthetic ligand Pam3CSK425. This ligand induced robust sprouting of EC from aortic rings of TLR2+/+ but not TLR2−/− mice (Fig. 2g). Pam3CSK4 was as effective as CEP or VEGF in tubulogenesis and cell adhesion assays, and the effect of Pam3CSK4 was eliminated by TLR2 antibodies (Supplementary Fig. 9b and 10a). To investigate the relative roles of CEP and VEGF, we examined the effect of a VEGF2 inhibitor, AAL-993, or TLR2 deletion in wound healing. Inhibiting either pathway had a similar effect and in combination led to additive inhibition of wound closure (Supplementary Fig. 10b).

Having established the role of TLR2 in the proangiogenic effects of CEP on ECs, we hypothesized that CEP administration might promote vascularization in ischemic or injured tissues. In a hind limb ischemia model, CEP-dipeptide injections resulted in 11-fold increase of the pyrrole adduct in muscle tissue (Supplementary Fig. 11a), which promoted re-vascularization of the ischemic limb (Fig. 3a) and restructuring of collateral blood vessels bypassing the ligated femoral artery (Supplementary Fig. 11b). Exogenous CEP affected vascularization in a TLR2-dependent manner (Fig 3a). Consequently, CEP injection increased blood flow in TLR2+/+ but not TLR2−/− mice (Fig. 3b). In a wound model, exogenous CEP accelerated wound closure and vascularization in TLR2+/+ but not TLR2−/− mice (Fig. 3c). Moreover, tumors implanted in TLR2−/− mice exhibited dramatically decreased vascularization and increased areas of necrosis (Supplementary Fig. 12).

Fig. 3Fig. 3Fig. 3
CEP-induced angiogenesis in vivo is mediated by TLR2

To distinguish the effect of CEP on ECs from that on leukocytes, TLR2+/+ and TLR2−/− mice were transplanted with TLR2+/+ bone marrow. In wound assays, CEP injection into TLR2+/+ >TLR2+/+ chimeras accelerated wound closure, whereas TLR2+/+ >TLR2−/− animals healed slower, and CEP had no effect on wound closure (Fig. 3d). The difference was associated with a 2.5-fold increase in vasculature by CEP treatment of TLR2+/+ but not TLR2−/− host animals (Fig. 3e). Even in the absence of exogenous CEP, vascular area was diminished in wounds of TLR2+/+ >TLR2−/− chimeras as compared to TLR2+/+ >TLR2+/+ (Fig. 3f). Moreover, melanoma vascularization in TLR2+/+ >TLR2−/− animals was reduced relative to TLR2+/+ >TLR2+/+ or TLR2−/− >TLR2+/+ chimeras (Fig. 3g). Thus, TLR2 on non-hematopoietic cells mediated vascularization induced by exogenous CEP and it also contributed to wound and tumor angiogenesis in the absence of an exogenous adduct.

Since CEP is accumulated at high levels during wound healing (Fig. 1 and Supplementary Fig. 2) and in tumors (Fig. 1d and Supplementary Fig. 3), we addressed the contribution of endogenously generated adducts to the process of vascularization in these models. Intravenous administration of neutralizing antibodies to CEP13, but not control antibodies, resulted in a more than 2-fold reduction of wound recovery (Fig. 4a). Vascularization of wounds was also inhibited by anti-CEP but not control antibodies, demonstrating the significance of endogenously generated CEP in wound angiogenesis (Fig. 4b and Supplementary Fig. 13). Remarkably, administration of anti-CEP, but not control antibodies, diminished progression and vascularization of melanoma and this effect was additive to that of the VEGFR inhibitor (Fig. 4c). Thus, the CEP/TLR2 axis drives VEGF-independent angiogenesis in a variety of pathological conditions.

Fig. 4Fig. 4Fig. 4
Endogenous CEP contributes to wound recovery and melanoma vascularization. TLR2-dependent responses to CEP involve MyD88 and Rac1

The key mechanism underlying the broad ligand specificity of TLR224 is its heterodimerization with other members of the TLR family, particularly TLR1 and TLR626. In a tube formation assay, anti-TLR1 and anti-TLR2, but not anti-TLR6 blocking antibodies, diminished the CEP-induced angiogenic response (Fig. 4d), indicating the involvement of TLR2/TLR1 heterodimers in CEP recognition. It appears that CEP directly interacts with TLR2, since recombinant TLR2 bound the CEP protein adduct but not the carrier protein alone (Supplementary Fig. 14a). Similar to other TLR2 ligands, CEP stimulated NF-κB in a cell-based assay (Supplementary Fig. 14b).

Next, we evaluated the role of MyD88, a mediator of TLR2 signaling, in the proangiogenic activity of CEP. CEP-induced EC sprouting is MyD88-dependent since MyD88−/− cells did not respond to stimulation by CEP (Fig. 4e). VEGF-induced angiogenesis was not affected by the lack of MyD88 (Fig. 4e). Considering that CEP-induced angiogenesis is integrin-dependent, we focused on mediators of integrin and TLR signaling. Rac1 mediates integrin-dependent migration in vascular development27 and is reported to be activated downstream of TLRs28. Accordingly, we assessed Rac1 GTP-loading in response to CEP treatment. GTP-bound Rac1 is increased by CEP treatment of TLR2+/+, but not TLR2−/− nor MyD88−/− cells (Fig. 4f). Thus, lipid oxidation products, represented by CEP, promote the angiogenic responses of ECs by activating TLR2 signaling in a MyD88-dependent manner, resulting in Rac1 activation, which, in turn, facilitates integrin function.

Altogether our results establish a novel mechanism of angiogenesis that is independent of hypoxia-triggered VEGF expression. The products of lipid oxidation are generated as a consequence of oxidative stress and are recognized by TLR2, possibly in a complex with TLR1 on ECs, and promote angiogenesis in vivo, thereby contributing to accelerated wound healing and tissue recovery. If high levels of CEP and its analogs accumulate in tissues, it may lead to excessive vascularization, e.g. in tumors. Contribution of the CEP/TLR2 axis to angiogenesis varies in different physiological settings possibly depending on the extent of oxidative stress. CEP-driven angiogenesis may be an attractive therapeutic target, especially in cancers resistant to anti-VEGF therapy. Inflammation and oxidation-driven angiogenesis may occur in other pathologies, for example atherosclerosis, where arterial thickening can depend on its microvasculature. In these settings, there is an extensive generation of oxidative products which might promote atherogenesis via TLR2. Indeed, it was shown that TLR2−/− mice are protected from atherosclerosis, and this effect could be mediated by cells other than bone marrow-derived29. Thus, along with pathogen- and danger-associated molecular patterns, TLR2 recognizes an oxidation-associated molecular pattern. This new function of TLR2 as a sensor of oxidative stress reveals the shortcut link between innate immunity, oxidation and angiogenesis.

Methods summary

Immunostaining was completed to assess the presence of endogenous CEP in various tissues. Tube formation assays, matrigel plug assays, wound healing assays, aortic ring assays, tumor implantation models, and a hind limb ischemia model evaluated the angiogenic effects of CEP and TLR2. TLR2+/+ and TLR2−/− mice were used for the above assays and in bone marrow transplantation studies. MyD88−/− mice and a commercially available Rac1 activation assay were used to examine the CEP/TLR2 signaling pathway.

Methods

Animal studies

Wild type C57BL/6 and DsRed transgenic mice were obtained from Jackson Laboratory, CD36−/− from Dr. M. Febbraio (Cleveland Clinic), SR-BI−/− from Dr. M. Krieger (Massachusetts Institute of Technology), MyD88−/− and TLR2−/− from Dr. S. Akira (Osaka University). All mice were maintained in the Biological Resources Unit of the Lerner Research Institute, accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. All experimental work was conducted in compliance with the Institutional Animal Care and Use Committee program.

Immunohistochemistry and image analysis

For immunofluorescence staining, we used rabbit polyclonal anti-CEP (described in5), anti-CD31 (BioLegend), anti-αSMA (Rockland), anti-CD68 (BD Biosciences) antibodies. We embedded samples in OCT freezing medium and prepared 7μm thick tissue sections. Sections were fixed in 4% paraformaldehyde. After incubation with primary antibodies, samples were washed with PBS and exposed to a Alexa Fluor-labeled secondary antibody, either goat anti-rabbit Alexa Fluor488, anti-rat Alexa Fluor568, or anti-mouse Alexa Fluor568 (Invitrogen). The slides were mounted with medium (DakoCytomation) and images were taken by either a TCS-SP (Leica) or a ZMZ1000 (Nikon) microscope. For quantification, the images were analyzed with ImagePro software (Media Cybernetics).

Bone marrow transplant (BMT) and wound assay

We performed BMT as previously described30. Briefly, we subjected two month old male wild type TLR2+/+ or TLR2−/− mice to irradiation with a total dose of 9 Gy followed by bone marrow reconstitution by tail vein injection with 107 bone marrow cells isolated from donor femurs. Eight weeks after BMT, mice were used for wound healing assays. A back punch wound healing model was used as described elsewhere31. Where indicated, mice were given CEP-dipeptide (M.W. 381.42) s.c injections (1.4 μg per g of body weight) at the time of injury and on days 2, 4, and 6. Separately, control mice were subjected to a back punch and injected s.c. with CEP-dipeptide (30 μg) and AAL-993 (13 nmol) every other day within 1 cm of the wound edge.

Aortic Ring Assay

The mouse aortic ring assay was performed as previously described32. Aortic rings were treated with CEP-dipeptide (0.5 μg/ml), VEGF (60 ng/ml) or Pam3CSK4 (300 nM).

Isolation of Endothelial cells

Mouse lungs were excised, minced, and digested using a collagenase-dispase reagent (Roche Diagnostic). Digests were strained and the resulting cell suspension was plated on flasks coated with 10 μg/ml fibronectin. Thereafter, endothelial cells were isolated and characterized as described previously32.

Tube formation assay

HUVEC or MLEC cells were seeded on Matrigel-coated plates (BD Bioscience). Medium was supplemented with VEGF (60 ng/ml) or protein adducts (0.5 μg/ml) as indicated, and cells were further incubated at 37°C for 8h. Anti-TLR2 blocking (developed by Dr. Salomon), anti-TLR4 blocking (BioLegend) and isotype control antibodies (IgG2a, BioLegend) or anti-TLR1 and anti-TLR6 blocking antibodies (InVivoGen) were added at 15 μg/ml at the beginning of the experiment. Alternatively, we incubated cells with 100 nM AAL-993 (Enzo Life Sciences). Tube formation was observed using a phase contrast inverted microscope, and photographs were taken from each well. The data were quantified by measuring the length of tubes with ImagePro software.

Matrigel plug assay

Matrigel (500μl) containing AAL-993 (200 nM) in combination with VEGF (250 ng) or CEP-dipeptide (10 μg/ml) was injected s.c. into C57BL/6 mice. Plugs were removed after 7 days and sectioned.

Hind limb ischemia model

The femoral artery was ligated near the caudally branching deep femoral artery and a second ligation was placed in proximity of the tibial artery branching. The portion of the artery and vein between the ligation points was excised. CEP-dipeptide was administered as PBS solution (1.4 μg per gram of body weight) injected intramuscularly distal to the ligation site, with injections every 48 hrs starting at the day of operation. Intramuscular CEP content was evaluated by immunohistochemistry and quantified using ImagePro software. Hind-limb blood flow was measured by a laser Doppler moorLDI2-IR near infra-red laser Class 3R (Moor Instruments) in arbitrary perfusion units (PU). The results were plotted as a ratio of operated to non-operated leg for each animal to account for variations between animals.

Tumor implantation

B16-F10 murine melanoma cells (ATCC) were injected subcutaneously (1.25×106 cells per injection) in wild type or BMT animals as indicated. Tumors were analyzed at day 10 post implantation. Mice were injected i.p. with AAL-993 (25 μmol), anti-CEP antibody (5 μg per gram body weight), or isotype control (IgG2a, 5 μg per gram body weight).

Rac1 activation assay

Per assay, we used 2×106 cells lysed in 500 μl buffer: 25 mM HEPES KOH pH 7.5, 250 mM NaCl, 1% NP-40, 10% glycerol, 10 mM MgCl2 2 mM EGTA. GST-PAK-PBD pre-absorbed on glutathione agarose beads (Cytoskeleton) was added in the amount of 20 μl 50% slurry followed by incubation on a rotary shaker for 45 min at 4°C. Beads were washed four times with lysis buffer before elution with SDSPAGE sample buffer. Rac1 was detected by Western Blot (clone 102, BD Bioscience).

Statistical analysis

All data are presented as mean ± s.e.m.. Probability values were based on a paired t test: NS represents not significant, * p<0.05, ** p<0.01, *** p<0.001.

Supplementary Material

all

Acknowledgments

This work was supported by NIH grants to T.V.B., E.A.P. and R.G.S. and an American Heart Association grant 10SDG4300062 to N.L.M. We express our gratitude to L. Hong for the help with synthesis of CEP and CPP adducts, Y. Cui for expressing and purifying anti-CEP monoclonal antibodies, and J. Crabb for providing anti-CEP mAb hybridoma cells.

Footnotes

Supplementary Information accompanies the paper on www.nature.com/nature.

Author contributions N.L.M., E.A.P., and T.V.B. designed experiments. In vivo and ex vivo experiments were performed by X.Z. with a help from A.A.M. and M.T. In vitro experiments were performed by with help from B.A.K. Melanoma samples and their analysis was done by E.C.B. Synthesis of CAPs was performed by R.G.S. The data were analyzed and plotted by X.Z. The manuscript was written by N.L.M. and T.V.B..

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests.

References

1. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997;11 (6):457–465. [PubMed]
2. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420 (6917):860–867. [PMC free article] [PubMed]
3. Mazzone M, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136 (5):839–851. [PubMed]
4. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. Dev Cell. 2009;16 (2):167–179. [PubMed]
5. Crabb JW, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99 (23):14682–14687. [PubMed]
6. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124 (4):823–835. [PubMed]
7. Martin P. Wound healing--aiming for perfect skin regeneration. Science. 1997;276 (5309):75–81. [PubMed]
8. Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature. 2009;459 (7249):996–999. [PMC free article] [PubMed]
9. Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197–223. [PMC free article] [PubMed]
10. Podrez EA, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002;277 (41):38503–38516. [PubMed]
11. Podrez EA, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13 (9):1086–1095. [PMC free article] [PubMed]
12. Gu X, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem. 2003;278 (43):42027–42035. [PubMed]
13. Ebrahem Q, et al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Proc Natl Acad Sci U S A. 2006;103 (36):13480–13484. [PubMed]
14. Manley PW, et al. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002;45 (26):5687–5693. [PubMed]
15. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 2009;227 (1):221–233. [PubMed]
16. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol. 2005;17 (4):338–344. [PubMed]
17. Shi H, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116 (11):3015–3025. [PMC free article] [PubMed]
18. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13 (9):1050–1059. [PubMed]
19. Kim HS, et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity. 2007;27 (2):321–333. [PubMed]
20. Vogl T, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13 (9):1042–1049. [PubMed]
21. Schaefer L, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115 (8):2223–2233. [PMC free article] [PubMed]
22. Jiang D, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11 (11):1173–1179. [PubMed]
23. Grote K, et al. Toll-like receptor 2/6 stimulation promotes angiogenesis via GMCSF as a potential strategy for immune defense and tissue regeneration. Blood. 115(12):2543–2552. [PubMed]
24. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. TLR2 -promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology. 2008;213 (3–4):205–224. [PubMed]
25. Aliprantis AO, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999;285 (5428):736–739. [PubMed]
26. Ozinsky A, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A. 2000;97 (25):13766–13771. [PubMed]
27. Tan W, et al. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J. 2008;22 (6):1829–1838. [PubMed]
28. Arbibe L, et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol. 2000;1 (6):533–540. [PubMed]
29. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005;115 (11):3149–3156. [PMC free article] [PubMed]
30. Chen J, et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med. 2005;11 (11):1188–1196. [PMC free article] [PubMed]
31. Feng W, et al. The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells. J Cell Biol. 2008;183 (6):1145–1157. [PMC free article] [PubMed]
32. Mahabeleshwar GH, Somanath PR, Byzova TV. Methods for isolation of endothelial and smooth muscle cells and in vitro proliferation assays. Methods Mol Med. 2006;129:197–208. [PubMed]